

Claim 40 (new): The use according to claim 33, wherein the insulin sensitiser is selected from troglitazone, ciglitazone, pioglitazone, englitazone and rosiglitazone.

Claim 41 (new): A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus, the prediabetic state and/or obesity in a mammal, which method comprises administering an effective amount of glutaminy l thiazolidine hydrochloride and metformin, to a mammal in need thereof.

Claim 42 (new): A pharmaceutical composition comprising glutaminy l thiazolidine or glutaminy l pyrrolidine, or a pharmaceutically acceptable salt thereof, and another antidiabetic agent, and a pharmaceutically acceptable carrier.

Claim 43 (new): A pharmaceutical composition according to claim 42 wherein the glutaminy l thiazolidine or glutaminy l pyrrolidine, or a pharmaceutically acceptable salt thereof, is glutaminy l thiazolidine hydrochloride.

Claim 44 (new): A pharmaceutical composition according to claim 42 or 43 wherein the other antidiabetic agent is as defined in claim 33.

Claim 45 (new): A pharmaceutical composition comprising glutaminy l thiazolidine hydrochloride and metformin.

No fee is deemed necessary in connection with the filing of this Preliminary Amendment. However, if any fee is required, the Commissioner is authorized to charge any deficiencies and credit any overpayment to OSI Pharmaceuticals, Inc. Deposit Account No. **502783**.

Respectfully submitted,

Dated: *28 Feb 2006*



---

Mr. Shu M. Lee  
Attorney for Applicant  
CUSTOMER NUMBER 38724  
Registration No. 41,147  
OSI Pharmaceuticals, Inc.  
58 South Service Road, Suite 110  
Melville, New York 11747  
Telephone: (631) 962-2056  
Facsimile: (631) 752-3880